Inicio › Cáncer de estómago › Pensilvania › Pittsburgh
Ensayos clínicos de Cáncer de estómago en Pittsburgh, PA
14 estudios para Cáncer de estómago buscan participantes en centros de Pittsburgh y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
Distance-Based Exercise to Preserve Function and Prevent Disability
Reclutando
- UPMC Hillman Cancer Center, Pittsburgh
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
ReclutandoFase 2/3
- UPMC Hillman Cancer Center, Pittsburgh
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
ReclutandoFase 2
- Research Site, Pittsburgh
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
ReclutandoFase 1
- University of Pittsburgh Medical Center, Pittsburgh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
ReclutandoFase 1/2
- Allegheny Health Network, Pittsburgh
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
ReclutandoFase 1
- UPMC Hillman Cancer Center, Pittsburgh
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
ReclutandoFase 3
- Research Site, Pittsburgh
- Research Site, Pittsburgh
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
ReclutandoFase 1/2
- University of Pittsburgh Medical Center, Pittsburgh
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
ReclutandoFase 1/2
- Research Site, Pittsburgh
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
ReclutandoFase 1
- University of Pittsburg Medical Center _UPMC Hillman Cancer Center, Pittsburgh
Lead-212 PSV359 Therapy for Patients With Solid Tumors
ReclutandoFase 1/2
- University of Pittsburgh Medical Center, Pittsburgh
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
ReclutandoFase 3
- UPMC Hillman Cancer Center, Pittsburgh
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
ReclutandoFase 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
ReclutandoFase 1
- AHN West Penn Hospital, Pittsburgh
Más información sobre Cáncer de estómago en MedlinePlus
Ensayos de Cáncer de estómago en otras ciudades
- Houston, TX42 estudios
- Boston, MA32 estudios
- New York City, NY31 estudios
- Nashville, TN28 estudios
- Baldwin Park, CA22 estudios
- Los Angeles, CA22 estudios
- Arlington, VA20 estudios
- Dallas, TX19 estudios
- San Antonio, TX19 estudios
- Grand Rapids, MI18 estudios
- St. Louis, MO18 estudios
- Chicago, IL16 estudios
Otros estudios en Pittsburgh
- Cáncer de pulmón de células no pequeñas48 estudios
- Cáncer (todos los tipos)41 estudios
- Cáncer de seno39 estudios
- Cáncer del colon y del recto32 estudios
- Cáncer metastásico31 estudios
- Melanoma31 estudios
- Cáncer de ovario30 estudios
- Cáncer de endometrio23 estudios
- Cáncer de próstata23 estudios
- Cáncer de pulmón23 estudios
- Carcinoma de células escamosas de cabeza y cuello22 estudios
- Accidente cerebrovascular22 estudios
De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.